All Type of News
Samsung Bioepis reveals clinical trial results of SB3 at ASCO in U.S.
Samsung Bioepis(CEO/President Han-Seung Ko) revealed the 1-year clinical trial result of SB3(Herceptin biosimilar, generic name: trastuzumab, European name: Ontruzant, Korean name: Samfenet), a breast cancer therapy.
...
Pharmaceutical Product Approval Renewal leads pharmas to reshuffle their products
The pharmaceutical product approval & registration renewal system starting last July was analyzed to lead the pharmaceutical industry to reshuffle their pharmaceutical products.
This is because 1 of 5 subjects to the...
‘Clinics’ and ‘dentists’ finally broke down the 2019 health care cost negotiation
The 2019 health care cost negotiation continued until 3am in the morning, but costs for ‘clinics’ and ‘dentists’ did not find a middle point.
The health care cost negotiation started at 8pm after the Financial Subcom...
Rapid decrease in generic approvals last year
The Ministry of Food and Drug Safety(MFDS) announced that 2,104 products(excluding oriental medicines and products for export) were approved and registered as medicine last year, decreased from 2,845 products of 2016,...
How listed pharmas did with overseas sales and exports?
This 1st quarter, both of KOSPI and KOSDAQ listed pharmaceutical companies has a decrease in overseas sales & exports on average compared to the same quarter of the last year.
Yakup Shinmoon(www.yakup.com) analyzed o...
LG Chem targets Japan with ‘Etanercept’ referencing Enbrel
LG Chem will aggressively target the Japanese ‘Etanercept’ market worth of KRW 400 billion.
When it comes to this news on the 30th, LG Chem completed registering health insurance benefit price of ‘Etanercept BS, refe...
MFDS additionally designates 104 products as national essential medicines
The Ministry of Food and Drug Safety(MFDS) announced on the 30th that they would be able to stably supply the total 315 ‘national essential medicines’ by additionally designating 104 medicinal drugs as ‘national essen...
KMP, the greatest variable for health care cost negotiation
Although the 2019 health care cost negotiation is about to be concluded today(31st), it seems they would have a hard time to close all the cases.
The Korean Medical Association(KMA) declared to leave the Health Insur...
Regarding Moon Jae-In Care covering MRIs, KMA says “one-sided action”
A meeting about the Moon Jae-In Care’s(National Health Insurance Coverage Extension Plan) coverage of MRI services for cerebrovascular diseases has been delayed due to conflicts between the government and associations...
Pharma industry being sensitive over what polices and prosecutors do
The pharmaceutical industry starts to get worried about illegal rebate investigation.
This is because the Seoul Western District Prosecutor’s Office, which made brilliant results in illegal rebate investigations amon...
